BioHarvest Sciences (BHST) vs Clene (CLNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Clene (CLNN) has outperformed BioHarvest Sciences (BHST) over the past year, losing 58.8% versus a loss of 88.2%. Over five years, BHST leads with a -84.5% price change compared with -96.9% for CLNN. Clene is the larger company by market cap ($55.2 million vs $33.9 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHST | CLNN |
|---|---|---|
| Share price | $1.50 | $3.88 |
| Market cap | $33.89M | $55.15M |
| 1-day change | +0.34% | -1.02% |
| YTD return | -71.19% | -33.90% |
| 1-year return | -88.18% | -58.81% |
| 5-year return | -84.47% | -96.86% |
| EPS (TTM) | $-0.51 | $-3.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.80 | $13.50 |
| 52-week low | $1.37 | $3.25 |
| Distance from 52-week high | -88.32% | -71.26% |
| Analyst consensus | none | none |
| Avg. price target upside | +602.34% | +729.90% |
| Average volume | 50.56K | 100.21K |
| Shares outstanding | 22.67M | 14.21M |
| Employees | 89 | 76 |
| Sector | Consumer Defensive | Consumer Defensive |
| Industry | Packaged Foods | Packaged Foods |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLNN has outperformed BHST by 29.4 percentage points over the past year.
About BioHarvest Sciences
BHST stock →BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States.
Consumer Defensive · Packaged Foods · 89 employees
About Clene
CLNN stock →Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Consumer Defensive · Packaged Foods · 76 employees
BHST vs CLNN FAQ
Which is bigger, BioHarvest Sciences or Clene?
Clene (CLNN) is larger, with a market capitalization of $55.15M compared with $33.89M for BioHarvest Sciences (BHST).
Which stock has performed better over the past year, BHST or CLNN?
CLNN returned -58.81% over the past 12 months, compared with -88.18% for BHST (price return, excluding dividends). Past performance does not predict future results.
Are BioHarvest Sciences and Clene in the same industry?
Yes. Both are classified in the Packaged Foods industry within the Consumer Defensive sector.